medigraphic.com
ISSN 1560-4381 (Print)

2017, Number 3

<< Back Next >>

Correo Científico Médico 2017; 21 (3)

Testosterone and prostate specific antigen in patients with prostatic carcinoma. Holguín province. 2013-2015

Ruiz LAI, Pérez MJC, Borrego CY, Cruz BY

Language: Spanish
References: 20
Page: 720-733
PDF size: 436.84 Kb.


ABSTRACT

Introduction: the increase of oncological diseases is taking on more and more lives in the world and in Cuba without distinction of race and age. At present this disease occupies an increasingly preponderant place in the world and is already the leading cause of death. Prostate cancer is the second leading cause of death in men worldwide and ranks fifth in the cause of this condition, with an estimated 30.000 new cases per year in the world.
Objective: to characterize the serum behavior of testosterone and specific prostatic antigen in patients with prostatic carcinoma, from 2013 to 2015 in the province of Holguín.
Methods: a retrospective cross-sectional descriptive study was carried out. The universe consisted of 104 patients diagnosed with prostate cancer at the Cancer Center of Vladimir I. Lenin Hospital. Descriptive indicators of the type of asolute, percentage, mean, standard deviation and coefficient of variation were used. The testosterone and specific prostatic antigen numbers were distributed in age groups and their serum values were associated.
Results: testosterone levels remained normal in 97.12% of cases, while levels of prostate specific antigen increased significantly in 85.57%. The age group with the most patients presented in both cases was 61 to 71 years.
Conclusions: this research confirmed that this neoplasia mainly affects the elderly and raises the specific prostatic antigen. The program established for an early diagnosis of this disease is necessary to be applied, which raises the possibility of a timely and effective treatment that facilitates the chances of cure and control of this illness.


REFERENCES

  1. Sagué JL. Urología. La Habana: Ciencias Médicas; 2012.

  2. Baumert H, Ballaro A, Dugardin F, Kaisary AV. Laparoscopic vesus open simple prostatectomy a comparative study. J Urol. 2006 [citado 10 jun 2016]; 175(5): 1691-16914. Disponible en: http://www.sciencedirect.com/science/article/pii/S0022534705009869

  3. Begg CB, Riede ER, Bach PB, Kattan MW, Schrag D, Warren JL, et.al. Variation in morbidity after radical prostatectomy. N Engl J Med. 2002 [citado 10 jun 2016]; 346(15):1138-1144. Disponible en: http://www.nejm.org/doi/full/10.1056/NEJMsa011788#t=article

  4. Bostwick DG. Evaluating prostate needle biopsy theraeutic and prognostic Importance. CA Cancer J Clin. 1997[citado 10 jun 2016]; 47(5):297-319. Disponible en: http://onlinelibrary.wiley.com/doi/10.3322/canjclin.47.5.297/full

  5. Prensner JR, Rubin MA, Wei JT, Chinnaiyan AM. Beyond PSA: The next generation of prostate cancer biomarkers. Sci Transl Med. 2012[citado 10 jun 2016]; 4(127). Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3799996/

  6. Curriel L, Chavier F, Souchon R, Birer A, Chapelon JY. 1.5-D high intensity focused ultrasound array for non-invasive prostate cancer surgery. IEEE Trans Ultrason Ferroelectr Freq Control. 2002 [citado 10 jun 2016]; 49(2):231-242.Disponible en: http://ieeexplore.ieee.org/document/985707/

  7. Dall'Oglio MF, Srougi M, Antunes AA, Crippa A, Cury J. An improved technique for controlling bleeding during simple retropubic prostatectomy. A randomized controlled study. BJU Int. 2006[citado 10 jun 2016]; 98(2): 384-387. Disponible en: http://onlinelibrary.wiley.com/doi/10.1111/j.1464-410X.2006.06236.x/full

  8. Djaladat H, Mehrsai A, Saraji A, Moosavi S, Djaladat Y, Pourmand G. Suprapubic prostate with a novel catheter. J Urol. 2006 [citado 2 feb 2013]; 175(6): 2083-2086. Disponible en: http://www.sciencedirect.com/science/article/pii/S0022534706003442

  9. Shalu J, Sunita S, Kumarb A. Epidemiology of prostate cancer in India. Meta Gene. 2014 [citado 2 feb 2015]; 2: 596–605. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4287887/

  10. Rodríguez Collar TL, Guzmán Cayado M, Rodríguez Batista R, Zamora González Y. Influencia de la hemodiálisis en los niveles del antígeno prostático específico. Rev Habanera Cienc Méd. 2015 [citado 2 mar 2017]; 14(6): 774-786. Disponible en: http://scieloprueba.sld.cu/scielo.php?script=sci_arttext&pid=S1729-519X2015000600007&lng=es.

  11. Mireku-Boateng AO, Jackson AG. Prostate fossa packing: Asimple quick and effective method of achieving hemostasis in suprapubic prostate cancer. Urol Int. 2005[citado 2 may 2013]; 74(2): 180-182. Disponible en: https://www.karger.com/Article/Abstract/83291

  12. Al-Aown A, Liatsikos E, Panagopoulos V, Kyriazis I, Kallidonis P, Georgiopoulos I2.et.al. Laparoscopic simple prostatectomy: A reasonable option for large prostatic adenomas. Urol Ann. 2015[citado 2 nov 2015]; 7(3): 297–302. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4518362/l

  13. Rüdiger JW, Forsberg JA, Wedin R. Surgery of skeletal metastases in 306 patients with prostate cancer. Acta Orthop. 2012[citado 5 abr 2013]; 83(1): 74–79. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278661/

  14. Sague Larrea JL, Franco Camejo L, Doimeadios Rodríguez Z. Análisis de la mortalidad por cáncer de próstata en pacientes de la provincia de Holguín. CCM. 2017 [citado 24 abr 2017]; 21(1). Disponible en: http://revcocmed.sld.cu/index.php/cocmed/article/view/1945

  15. González Rodríguez R, Cardentey García J. Realización del antígeno prostático específico desde el primer nivel de atención médica. Rev Cubana Med Gen Integr. 2016[citado 24 abr 2017]; 32(2):153-160.Disponible en: http://scieloprueba.sld.cu/scielo.php?script=sci_arttext&pid=S0864-21252016000200002&lng=es

  16. Ortiz J, Almoguer E. La eficiencia del índice de PSA libre en el diagnóstico del cáncer de próstata. An Fac Med. 2015[citado 24 abr 2017]; 76(1): 27-32.Disponible en: http://www.redalyc.org/articulo.oa?id=37938589005&idioma=es

  17. Fernández Marichal FS, Toirán García R, Varela Álvarez A, Segura Roque O. Cáncer prostático: correlación entre el valor del antígeno prostático específico y el resultado anatomoclínico. AMC. 2015[citado 24 abr 2017]; 19(1):42-49. Disponible en: http://scieloprueba.sld.cu/scielo.php?script=sci_arttext&pid=S1025-02552015000100008&lng=es

  18. Barrios López Y, Perera Fernández F, Carvajal Beltrán II, Pérez Rodríguez A. Pesquisa de cáncer de próstata en 8 áreas de salud de la provincia de Santiago de Cuba. MEDISAN. 2012 [citado 2017 Abr 24]; 16(3): 376-382. Disponible en: http://scieloprueba.sld.cu/scielo.php?script=sci_arttext&pid=S1029-30192012000300010&lng=es

  19. López Ríos L, Sánchez Montero IR, García Moreno I. Relación entre el marcador tumoral antígeno prostático específico y la mortalidad por cáncer de próstata. CCM. 2017 [citado 24 abr 2017]; 21(1). Disponible en: http://revcocmed.sld.cu/index.php/cocmed/article/view/2390

  20. Valiente Morejón W, Junco Sena B, Padrón Vega Y, Ramos Águila Y, Castillo García I. Antígeno prostático específico como predictor del diagnóstico de adenocarcinoma prostático. Rev Finlay. 2015[citado 24 abr 2017]; 5(4):221-227. Disponible en: http://scieloprueba.sld.cu/scielo.php?script=sci_arttext&pid=S2221-24342015000400002&lng=es




2020     |     www.medigraphic.com